Beta 2 Glycoprotein 1 - IgG
Blood0 parametersReport in 4HrsAt Home
No Fasting Required
Details
These antiphospholipid antibodies can increase the risk of abnormal blood clotting (thrombosis) and complications in pregnancy
₹929₹1,100
16% OFF
FREE:AI Insights
Beta 2 Glycoprotein 1 - IgG Test Guide
- Why is it done?
- Detects IgG antibodies against Beta 2 Glycoprotein 1, a blood protein involved in blood clotting and immune regulation
- Diagnoses Antiphospholipid Syndrome (APS), an autoimmune disorder that increases risk of blood clots and pregnancy complications
- Evaluates patients with unexplained blood clots (thrombosis) in veins or arteries
- Investigates recurrent pregnancy losses or complications (miscarriage, stillbirth, preeclampsia)
- Screens patients with systemic lupus erythematosus (SLE) and other autoimmune diseases
- Monitors disease activity and treatment response in diagnosed APS patients
- Typically ordered when clinical suspicion for APS is high or as part of thrombophilia workup
- Normal Range
- Negative or Low: < 15 GPL (Glycoprotein units) - Normal and reassuring result
- Borderline/Low-Positive: 15-20 GPL - Weak positive; may require repeat testing or clinical correlation
- Moderate-Positive: 20-80 GPL - Significant level consistent with APS
- High-Positive: > 80 GPL - Strong positive associated with high thrombotic risk
- Units: GPL-Units (Glycoprotein Units per milliliter); reference ranges may vary slightly by laboratory
- Normal result: Indicates no detectable IgG antibodies against Beta 2 Glycoprotein 1; low APS probability
- Abnormal result: Positive result suggests autoimmune antibody production; requires clinical correlation for APS diagnosis
- Interpretation
- Negative Result (< 15 GPL): No significant anti-Beta 2 Glycoprotein 1 IgG antibodies detected; APS is unlikely but cannot be completely excluded if only one test performed; consider testing for other antiphospholipid antibodies (Lupus Anticoagulant, anti-Cardiolipin IgG/IgM) if clinical suspicion remains high
- Borderline/Low-Positive (15-20 GPL): Weakly positive result; clinical significance uncertain; repeat testing in 12 weeks required per diagnostic criteria; may represent transient antibodies from infection or early disease; correlation with symptoms and other test results essential
- Moderate-Positive (20-80 GPL): Clearly elevated; supports APS diagnosis when combined with clinical features and positive confirmatory tests; indicates persistent autoimmune response; associated with increased thrombotic risk
- High-Positive (> 80 GPL): Markedly elevated; strong indicator of APS; associated with significantly elevated thrombotic risk and obstetric complications; may predict more severe disease; strong recommendation for anticoagulation therapy consideration
- Factors Affecting Results:
- Recent infections (viral, bacterial) may cause transient positivity
- Concurrent autoimmune diseases (SLE, Sjögren's syndrome) may increase antibody levels
- Medications: Certain drugs (hydralazine, procainamide) may induce positive results
- Timing of testing relative to thrombotic events may affect antibody levels
- Anticoagulation therapy does not typically affect antibody detection
- Clinical Significance:
- APS diagnosis requires: (1) clinical criteria (thrombosis or obstetric manifestations) AND (2) laboratory criteria (positive antiphospholipid antibodies on two occasions ≥12 weeks apart)
- Triple positivity (positive for Lupus Anticoagulant, anti-Cardiolipin, and anti-Beta 2 Glycoprotein 1 IgG) indicates highest thrombotic risk
- Persistently positive results carry more clinical significance than transient positivity
- Associated Organs
- Primary Organ Systems Involved:
- Circulatory/Vascular System: Blood vessels and coagulation cascade affected by abnormal antibodies leading to thrombosis
- Immune System: Autoimmune dysfunction produces abnormal IgG antibodies against phospholipid-binding protein
- Reproductive System: Placental complications leading to pregnancy loss and obstetric morbidity
- Diseases Commonly Associated with Abnormal Results:
- Antiphospholipid Syndrome (APS) - Primary condition; autoimmune disease causing recurrent thrombosis and pregnancy complications
- Systemic Lupus Erythematosus (SLE) - 30-40% of SLE patients have antiphospholipid antibodies; secondary APS
- Sjögren's Syndrome - Associated with antiphospholipid antibodies in 40% of cases
- Rheumatoid Arthritis - May have concurrent antiphospholipid antibodies
- Catastrophic Antiphospholipid Syndrome (CAPS) - Rare, life-threatening thrombotic microangiopathy with multiple organ involvement
- Potential Complications Associated with Abnormal Results:
- Venous thromboembolism: Deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Arterial thrombosis: Stroke, myocardial infarction, peripheral arterial thrombosis
- Obstetric complications: Recurrent miscarriage, stillbirth, intrauterine growth restriction, preeclampsia, placental insufficiency
- Thrombotic microangiopathy: Hemolytic anemia, thrombocytopenia, organ dysfunction
- Skin manifestations: Livedoid vasculopathy, superficial thrombophlebitis
- Neurological complications: Transient ischemic attacks, cognitive dysfunction, seizures
- Follow-up Tests
- Confirmatory and Complementary Tests:
- Lupus Anticoagulant (LA) - Required for APS diagnosis; functional coagulation test; ordered if Beta 2 Glycoprotein 1 IgG is positive
- Anti-Cardiolipin IgG and IgM - Part of antiphospholipid antibody panel; helps establish diagnosis; triple positivity indicates highest risk
- Anti-Phosphatidylserine/Prothrombin Complex (aPS/PT) - Emerging marker for APS; may be ordered in specialized centers
- Repeat Testing Requirements:
- Borderline positive (15-20 GPL) requires repeat testing at 12 weeks per Revised Sydney Criteria for APS diagnosis confirmation
- Positive results warrant repeat testing to confirm persistence of antibodies
- Monitoring interval: Re-test every 3-6 months in established APS patients to assess disease activity
- Additional Diagnostic Tests to Consider:
- Activated Partial Thromboplastin Time (aPTT) - May be prolonged in presence of Lupus Anticoagulant; assess clotting function
- Prothrombin Time (PT) and International Normalized Ratio (INR) - Establish baseline before anticoagulation; monitor during therapy
- Platelet Count - Assess for thrombocytopenia associated with APS
- Antinuclear Antibody (ANA) and Anti-dsDNA - Screen for concurrent SLE or autoimmune disease
- Imaging Studies - Doppler ultrasound, CT angiography, or MRI may be ordered based on clinical presentation to identify thrombosis
- Complete Blood Count (CBC) - Monitor for cytopenias in systemic involvement; evaluate hemolytic anemia
- Comprehensive Metabolic Panel (CMP) - Assess organ function (renal, hepatic) in context of systemic disease
- Monitoring Frequency in Diagnosed APS:
- Stable patients on anticoagulation: Monitor INR/coagulation studies per protocol (typically monthly, then every 4-12 weeks)
- Antiphospholipid antibody re-testing: 3-6 months after initial diagnosis to confirm persistence
- Pregnancy monitoring: Pregnant patients require frequent clinical and laboratory assessments
- Fasting Required?
- Fasting Required: No - Fasting is NOT required for Beta 2 Glycoprotein 1 - IgG testing. Blood sample can be collected at any time of day regardless of food intake.
- Patient Preparation Instructions:
- No special food or fluid restrictions needed
- No fasting period required; can be tested any time of day
- Bring valid photo identification and insurance card to laboratory appointment
- Continue regular medications unless specifically instructed otherwise by physician
- Medications:
- No medications need to be withheld; anticoagulant therapy (warfarin, heparin, DOACs) does not interfere with antibody detection
- Inform laboratory staff of all current medications for reference purposes
- Corticosteroids or immunosuppressive agents do not significantly affect test results but should be documented
- Additional Preparation:
- Avoid strenuous exercise immediately before testing if possible
- Maintain regular hydration; dehydration may affect lab results
- Sample collection: Blood drawn via venipuncture into appropriate collection tube (typically purple-top EDTA or serum separator tube)
- Inform phlebotomist of any bleeding disorders, current anticoagulation, or difficult venous access history
- Test turnaround time: Typically 2-5 business days; may be expedited in urgent clinical situations
How our test process works!
